Intrinsic Merges with PBAX
The resources of the combined company look to provide Intrinsic with the capital to advance OM002, a synthetic biology-produced HMO drug candidate.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.